DRD1 and Dyskinesia: Figure 6 showed β-arrestin2 knockdown augment the dyskinesia behavior was apparently reversed by SCH23390 (0.25 mg/kg), a D1R antagonist, in terms of total AIMs (n = 4 for each group, total 4*4=16, p < 0.